Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 396.49M P/E - EPS this Y -8.40% Ern Qtrly Grth -
Income -125.04M Forward P/E -2.31 EPS next Y -6.70% 50D Avg Chg -4.00%
Sales - PEG 0.13 EPS past 5Y - 200D Avg Chg -36.00%
Dividend N/A Price/Book 1.03 EPS next 5Y -15.90% 52W High Chg -76.00%
Recommedations 2.00 Quick Ratio 11.98 Shares Outstanding 151.49M 52W Low Chg 7.00%
Insider Own 20.34% ROA -19.44% Shares Float 85.72M Beta 1.10
Inst Own 47.50% ROE -34.33% Shares Shorted/Prior 9.48M/9.02M Price 2.63
Gross Margin - Profit Margin - Avg. Volume 614,520 Target Price 7.50
Oper. Margin - Earnings Date - Volume 302,927 Change -0.75%
About Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Erasca, Inc. News
04/24/24 Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
04/23/24 Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
04/16/24 Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
04/01/24 Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
03/29/24 Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
07:30 PM Erasca Announces $45 Million Oversubscribed Private Placement Financing
03:01 PM Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
02/14/24 Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
02/01/24 Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/09/24 Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?
01/03/24 Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/20/23 3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
12/13/23 Erasca Co-Founder Acquires 3.2% More Stock
12/11/23 Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
11/28/23 Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
11/09/23 Erasca Reports Third Quarter 2023 Financial Results and Business Updates
11/08/23 Erasca to Present at Upcoming Investor Conferences in November
11/08/23 With 31% ownership, Erasca, Inc. (NASDAQ:ERAS) has piqued the interest of institutional investors
10/12/23 Insiders Are Betting Millions on These 2 Stocks — Here’s Why You Might Want to Follow Their Lead
10/12/23 Insider Spends US$2.0m Buying More Shares In Erasca
ERAS Chatroom

User Image Tacto Posted - 15 hours ago

$ERAS That's a current snapshot of EDGX here in after-hours He still has his phony 20k on the $1.95 offer. It's not an iceberg order, as we can clearly see that he's running the very same routine he did in late January and the beginning of February, and that 20k will simply vanish with no corresponding transaction. It's a harvesting program. He's simply suppressing the stock to discourage others, while building an extra fat holding..

User Image Tacto Posted - 16 hours ago

$ERAS Here's the candle picture at 1-hour resolution. Check out the volume bars at the bottom..

User Image Tacto Posted - 16 hours ago

$ERAS Update of official FDA record for SEACRAFT-2 clinical trial just posted today, showing one new location https://classic.clinicaltrials.gov/ct2/history/NCT06346067?A=1&B=2&C=Side-by-Side#StudyPageTop

User Image Tacto Posted - 16 hours ago

$ERAS Update of official FDA record for SEACRAFT-1 clinical trial just posted today, showing 5 sites started recruiting, and 2 withdrawn https://classic.clinicaltrials.gov/ct2/history/NCT05907304?A=15&B=16&C=Side-by-Side#StudyPageTop

User Image OnTheBalance Posted - 1 day ago

@Tshanky_ if you are swinging for 100% .. all the best to you. I am investing in and hoarding $ERAS shares with a 10x + bagger in mind. One of the rare ones ✅

User Image Tshanky_ Posted - 1 day ago

$ERAS

User Image Tshanky_ Posted - 1 day ago

$ERAS

User Image Tacto Posted - 2 days ago

$ERAS That crime syndicate operator spoofing 20k on the $1.95 offer on EDGX here in the pre-market today was doing the same thing during regular hours yesterday. He's evidently scared of something.. https://www.cboe.com/us/equities/market_statistics/book/eras/

User Image Tacto Posted - 2 days ago

$ERAS Holy mackerel! That crime syndicate operator just moved 3.2M into the shorting pool. Availability had been 2.1M earlier this morning, and now it's 5.3M Let's see what this is all about... https://fintel.io/ss/us/eras

User Image Stock_Titan Posted - 2 days ago

$ERAS Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting https://www.stocktitan.net/news/ERAS/erasca-announces-three-presentations-at-the-2024-asco-annual-niwa4c13kmof.html

User Image Quantumup Posted - 3 days ago

JonesResearch raised the PT on $DAWN to $38 was $35, and reiterated a Buy rating + raised peak adjusted sales estimates to approx. $900M from $750M in 2033, after⬆️OJEMDA (tovorafenib) pricing to $33.9K/month from $28K/month, included 20% GTN discount, and 20% towards PAP, to reflect Co's announced pricing: "The FDA approved Day One Biopharma's lead drug, OJEMDA (tovorafenib), in relapse/refractory low grade glioma in 6 months or older in BRAF altered or V600E mutant patients. Increasing POS in r/r pLGG to 100%, raised drug price to $33.9K/month from $28K/month, included 20% GTN discount, and 20% towards PAP. Our peak adjusted sales raised to approx. $900MN from $750MN in 2033. With modest changes across the model, our PT raised to $38 from $35, reiterating BUY." $eras

User Image Quantumup Posted - 3 days ago

TD Cowen remains at a Buy rating on $DAWN "on the long term pLGG opportunity," and views "the label as a nearly best case representing modest upside vs. expectations:" "The FDA granted Ojemda (tovorafenib) accelerated approval for r/r pLGG with any BRAF alteration rather than just fusions as some had feared. Efficacy data also contained MRs that bears felt "didn't count." Finally, no AEs rose to the level of a black box. We view the label as a nearly best case representing modest upside vs. expectations and remain at Buy on the long term pLGG opportunity." $eras

User Image signaljumper Posted - 3 days ago

$ERAS all 7ndef 2$ is in buying area

User Image Quantumup Posted - 3 days ago

JPMorgan says they see $DAWN (Overweight/$36) shares moving to the "high-teens to low-$20s" level given the clean label and early approval. Additionally, JPM expects a strong launch given the unmet need, w/ shares going to the mid-$20s over time. $eras

User Image signaljumper Posted - 4 days ago

$ERAS loading time

User Image reces1 Posted - 5 days ago

$ERAS May be time to scare the shorts?

User Image Tacto Posted - 5 days ago

$ERAS That crime syndicate operator just withdrew a whopping 2.6M from the shorting pool this morning. You might recall that they added 2.2M on April 11th, right before they proceeded to hose the stock down for more than a week straight. Like I said a while back, the big drubbing was done by totally artificial means, so we can expect a pretty f'n significant rebound from that ridiculousness... https://fintel.io/ss/us/eras

User Image OnTheBalance Posted - 5 days ago

@NeverPop @reces1 @cklee88 a simpler plan is to keep adding as many shares as one can within the context of their overall portfolio and risk tolerance. $ERAS is one of my conviction holdings in the high risk segment of my portfolio

User Image moneyboy77 Posted - 1 week ago

$ERAS whats the newsflow here over the next 6 months ? check IMMP !

User Image Tacto Posted - 1 week ago

$ERAS Lower BB support today ($1.79), and the picture at 30-minute resolution has 'reversal' written all over it

User Image Tacto Posted - 1 week ago

$ERAS Primarily buying today. See all those big, green volume bars. Reversal...

User Image Tacto Posted - 1 week ago

$ERAS Stochastic Buy Signal The slow (blue) crossed above the fast (red) in oversold territory (<20%), as you can see in the lower part of the picture

User Image yus37 Posted - 1 week ago

$XBI $PACB $ADPT $ERAS $PASG 👀

User Image rangerhawkeye Posted - 1 week ago

@NumberWang I agree, but $ERAS was called out as being a good investment also and that was 2.50 recently. $ESPR takes more of a negative stance because of Sheldon’s history

User Image cklee88 Posted - 1 week ago

$ERAS info leak?

User Image toro7 Posted - 1 week ago

$ERAS adding.

User Image Tacto Posted - 1 week ago

$ERAS EDBI reported Q1 today, showing they held their 888,888 shares that they got at an estimated average cost of $18.08 each

User Image Tacto Posted - 1 week ago

$ERAS Stochastic Buy Signal will likely be triggered tomorrow. You can see in the lower part of the picture where the slow stochastic (blue) has turned at rock-bottom on the scale, and it is now poised to cross above the fast (red) in oversold territory (<20%) I'm continuing to add in this wholly-manufactured/artificially-contrived and tremendously oversold scenario. An extra fat rebound is on tap! 🛸

User Image OnTheBalance Posted - 1 week ago

$ERAS I do not mind current stock price compression, more shares for hoarding 🤫

User Image reces1 Posted - 1 week ago

$ERAS Another day of all buys falling under the ASK. All sells hitting the mark. Shorts in total control of this one for the foreseeable future.

Analyst Ratings
Goldman Sachs Buy Apr 2, 24
HC Wainwright & Co. Buy Mar 28, 24
Capital One Overweight Mar 11, 24
B of A Securities Neutral Jan 5, 24
Mizuho Buy Nov 29, 23
HC Wainwright & Co. Buy Nov 28, 23
HC Wainwright & Co. Buy Oct 11, 23
Evercore ISI Group Outperform Jun 6, 23
Mizuho Buy Jun 6, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Start Valerie Denise Harding Director Director Dec 06 Buy 1.848 10,000 18,480 20,000 12/08/23
Lim Jonathan E Chairman & CEO Chairman & CEO Dec 05 Buy 1.7 1,000,000 1,700,000 12,899,360 12/06/23
Casdin Alexander W. Director Director Dec 04 Buy 1.6595 30,000 49,785 493,974 12/04/23
Lim Jonathan E Chairman & CEO Chairman & CEO Oct 05 Buy 2.026 1,000,000 2,026,000 19,456,216 10/10/23
Lim Jonathan E Chairman & CEO Chairman & CEO Jun 08 Buy 2.75 100,000 275,000 18,396,216 06/08/23
Casdin Alexander W. Director Director Apr 10 Buy 2.7615 20,000 55,230 463,974 04/11/23
Lim Jonathan E Chairman & CEO Chairman & CEO Mar 28 Buy 2.84 100,000 284,000 18,296,216 03/28/23
Start Valerie Denise Harding Director Director Dec 21 Buy 4.64 10,000 46,400 10,000 12/22/22
Bristol James Arthur Director Director Dec 21 Buy 4.14 20,000 82,800 20,000 12/22/22
Chen Bihua Director Director Dec 13 Buy 6.5 307,692 1,999,998 10,813,246 12/21/22
Chen Bihua Director Director Dec 20 Buy 6.5 307,692 1,999,998 10,813,246 12/20/22
Lim Jonathan E Chairman & CEO Chairman & CEO Dec 14 Buy 4.99 40,000 199,600 20,196,222 12/15/22